CD20

[Scientific Reports] Scientists investigated the impact of pretransplant desensitization with rituximab on anti-donor T cell responses in donor-specific anti-human leukocyte antigen antibody-positive transplant recipients.

[Blood Advances] The authors conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20+, Philadelphia-negative precursor B-ALL; bone marrow measurable residual disease negativity at the end of induction was the primary end point.

[Blood Advances] Researchers conducted a Phase II study to test the activity of bortezomib and rituximab in combination with a pediatric-inspired regimen during induction therapy in newly diagnosed adolescents and adults with CD20-positive, Philadelphia (Ph)-negative precursor B-cell acute lymphoblastic leukemia.

[Journal of Controlled Release] Scientists highlight recent advance in targeted polymeric nanoformulations that are coated with varying ligands and loaded with different therapeutic agents for directing to distinct targets in hematological malignancies.

[Proceedings of the National Academy of Sciences of the United States of America] To advance the development of natural killer (NK)-based therapies, scientists developed a functional screen to rapidly identify antibodies that can activate NK cells. They displayed antibodies on a mammalian target cell line and probed their ability to stimulate NK cell-mediated cytotoxicity.

[Journal of Pathology] The authors characterized and assessed the prognostic potential of distinct immune cell infiltration patterns in the prostate tumor microenvironment.